Literature DB >> 18632556

Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease.

Melanie D White1, Michael Farmer, Ilaria Mirabile, Sebastian Brandner, John Collinge, Giovanna R Mallucci.   

Abstract

Prion diseases are fatal neurodegenerative conditions for which there is no effective treatment. Prion propagation involves the conversion of cellular prion protein, PrP(C), to its conformational isomer, PrP(Sc), which accumulates in disease. Here, we show effective therapeutic knockdown of PrP(C) expression using RNAi in mice with established prion disease. A single administration of lentivirus expressing a shRNA targeting PrP into each hippocampus of mice with established prion disease significantly prolonged survival time. Treated animals lived 19% and 24% longer than mice given an "empty" lentivirus, or not treated, respectively. Lentivirally mediated RNAi of PrP also prevented the onset of behavioral deficits associated with early prion disease, reduced spongiform degeneration, and protected against neuronal loss. In contrast, mice receiving empty virus or no treatment developed early cognitive impairment and showed severe spongiosis and neuronal loss. The focal use of RNAi therapeutically in prion disease further supports strategies depleting PrP(C), which we previously established to be a valid target for prion-based treatments. This approach can now be used to define the temporal, quantitative, and regional requirements for PrP knockdown for effective treatment of prion disease and to explore mechanisms involved in predegenerative neuronal dysfunction and its rescue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632556      PMCID: PMC2474561          DOI: 10.1073/pnas.0802759105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  31 in total

1.  Impaired recognition memory in rats after damage to the hippocampus.

Authors:  R E Clark; S M Zola; L R Squire
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

2.  Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery.

Authors:  N D Mazarakis; M Azzouz; J B Rohll; F M Ellard; F J Wilkes; A L Olsen; E E Carter; R D Barber; D F Baban; S M Kingsman; A J Kingsman; K O'Malley; K A Mitrophanous
Journal:  Hum Mol Genet       Date:  2001-09-15       Impact factor: 6.150

3.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference.

Authors:  Douglas A Rubinson; Christopher P Dillon; Adam V Kwiatkowski; Claudia Sievers; Lili Yang; Johnny Kopinja; Dina L Rooney; Mingdi Zhang; Melanie M Ihrig; Michael T McManus; Frank B Gertler; Martin L Scott; Luk Van Parijs
Journal:  Nat Genet       Date:  2003-02-18       Impact factor: 38.330

4.  Comparison of the neuropathological characteristics of bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (vCJD) in mice.

Authors:  D A Brown; M E Bruce; J R Fraser
Journal:  Neuropathol Appl Neurobiol       Date:  2003-06       Impact factor: 8.090

5.  Synaptic changes characterize early behavioural signs in the ME7 model of murine prion disease.

Authors:  C Cunningham; R Deacon; H Wells; D Boche; S Waters; C Picanco Diniz; H Scott; J N P Rawlins; V H Perry
Journal:  Eur J Neurosci       Date:  2003-05       Impact factor: 3.386

6.  Specific inhibition of pathological prion protein accumulation by small interfering RNAs.

Authors:  Nathalie Daude; Mathieu Marella; Joelle Chabry
Journal:  J Cell Sci       Date:  2003-05-20       Impact factor: 5.285

7.  Efficient and specific down-regulation of prion protein expression by RNAi.

Authors:  G Tilly; J Chapuis; D Vilette; H Laude; J L Vilotte
Journal:  Biochem Biophys Res Commun       Date:  2003-06-06       Impact factor: 3.575

8.  Efficient gene transfer via retrograde transport in rodent and primate brains using a human immunodeficiency virus type 1-based vector pseudotyped with rabies virus glycoprotein.

Authors:  Shigeki Kato; Ken-ichi Inoue; Kenta Kobayashi; Yasunobu Yasoshima; Shigehiro Miyachi; Satoshi Inoue; Hideki Hanawa; Takashi Shimada; Masahiko Takada; Kazuto Kobayashi
Journal:  Hum Gene Ther       Date:  2007-11       Impact factor: 5.695

9.  Post-natal knockout of prion protein alters hippocampal CA1 properties, but does not result in neurodegeneration.

Authors:  G R Mallucci; S Ratté; E A Asante; J Linehan; I Gowland; J G R Jefferys; J Collinge
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

10.  Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.

Authors:  Giovanna Mallucci; Andrew Dickinson; Jacqueline Linehan; Peter-Christian Klöhn; Sebastian Brandner; John Collinge
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

View more
  79 in total

1.  Sustained translational repression by eIF2α-P mediates prion neurodegeneration.

Authors:  Julie A Moreno; Helois Radford; Diego Peretti; Joern R Steinert; Nicholas Verity; Maria Guerra Martin; Mark Halliday; Jason Morgan; David Dinsdale; Catherine A Ortori; David A Barrett; Pavel Tsaytler; Anne Bertolotti; Anne E Willis; Martin Bushell; Giovanna R Mallucci
Journal:  Nature       Date:  2012-05-06       Impact factor: 49.962

2.  Slit2/Robo1 Mediation of Synaptic Plasticity Contributes to Bone Cancer Pain.

Authors:  Changbin Ke; Feng Gao; Xuebi Tian; Caijuan Li; Dai Shi; Wensheng He; Yuke Tian
Journal:  Mol Neurobiol       Date:  2016-01-06       Impact factor: 5.590

3.  Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development.

Authors:  Sonia M Vallabh; Chloe K Nobuhara; Franc Llorens; Inga Zerr; Piero Parchi; Sabina Capellari; Eric Kuhn; Jacob Klickstein; Jiri G Safar; Flavia C Nery; Kathryn J Swoboda; Michael D Geschwind; Henrik Zetterberg; Steven E Arnold; Eric Vallabh Minikel; Stuart L Schreiber
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-01       Impact factor: 11.205

4.  The suppression of prion propagation using poly-L-lysine by targeting plasminogen that stimulates prion protein conversion.

Authors:  Chongsuk Ryou; William B Titlow; Charles E Mays; Younsoo Bae; Sehun Kim
Journal:  Biomaterials       Date:  2011-02-01       Impact factor: 12.479

Review 5.  Copper-dependent regulation of NMDA receptors by cellular prion protein: implications for neurodegenerative disorders.

Authors:  Peter K Stys; Haitao You; Gerald W Zamponi
Journal:  J Physiol       Date:  2012-02-06       Impact factor: 5.182

Review 6.  Experimental animal model and RNA interference: a promising association for bladder cancer research.

Authors:  Leonardo Oliveira Reis; Tiago Campos Pereira; Wagner José Favaro; Valéria Helena Alves Cagnon; Iscia Lopes-Cendes; Ubirajara Ferreira
Journal:  World J Urol       Date:  2009-02-13       Impact factor: 4.226

Review 7.  Gene therapy for misfolding protein diseases of the central nervous system.

Authors:  Waldy San Sebastian; Lluis Samaranch; Adrian P Kells; John Forsayeth; Krystof S Bankiewicz
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

8.  Prion permissive pathways: extracellular matrix genes control susceptibility to prion infection.

Authors:  Thibaut Imberdis; David A Harris
Journal:  EMBO J       Date:  2014-06-21       Impact factor: 11.598

9.  Insights into prion biology: integrating a protein misfolding pathway with its cellular environment.

Authors:  Susanne DiSalvo; Tricia R Serio
Journal:  Prion       Date:  2011-04-01       Impact factor: 3.931

10.  Establishment of a simple cell-based ELISA for the direct detection of abnormal isoform of prion protein from prion-infected cells without cell lysis and proteinase K treatment.

Authors:  Zhifu Shan; Takeshi Yamasaki; Akio Suzuki; Rie Hasebe; Motohiro Horiuchi
Journal:  Prion       Date:  2016-07-03       Impact factor: 3.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.